Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...

Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.

A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...

Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...

Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...

Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...

AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of ...

Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...

Nicholas Johnston launches Alis Biosciences, targeting struggling biotechs with $30B in trapped capital and aiming to return ...

ALX On­col­o­gy’s ef­forts to progress a CD47 com­bo hit a ma­jor speed bump. The com­pa­ny said Fri­day that two tri­als ...

Only 66% of FDA-approved biosimilars launched, with Humira & Enbrel facing limited competition despite biosimilars priced ...